Skip to main content

Switzerland excels with biotech start-ups

biotechnology
| News

Switzerland excels with biotech start-ups

06.05.2019

According to an article in the journal “Nature”, Switzerland is the European leader with its biotech start-up ecosystem. Based on population size, Switzerland ranks in first place for both venture capital and patent and research output.

biotechnology
Biotech (img: angellodeco/shutterstock)

An article in the journal “Nature” examines the European biotech start-up ecosystem and compares the ecosystems in the individual countries. For example, it measures the number of biotech start-ups that were able to raise venture capital between 2013 and 2017. In absolute numbers, the UK leads followed by France and Switzerland. However, Switzerland ranks the highest based on population size, followed by Denmark and Ireland in second place.

In addition to venture capital raised, the article also looks at research productivity. Per capita Switzerland is also the leader in this field across Europe, followed by Denmark, Sweden and the Netherlands. According to the article, this can be explained by the high level of R&D spending. At 3.4%, Switzerland is also the European country with the highest R&D spending as a percentage of gross domestic product (GDP).

On a per capital basis, Switzerland also ranks highest across Europe in terms of biotech patents. It also performs well in the area of human capital and is in third place behind Denmark and the Netherlands based on the number of clinical trials per capita.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.